The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.

Autor: Hondelink LM; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Schrader AMR; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Asri Aghmuni G; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Solleveld-Westerink N; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Cleton-Jansen AM; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., van Egmond D; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Boot A; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Ouahoud S; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Khalifa MN; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Wai Lam S; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Morreau H; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Bovee JVMG; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., van Wezel T; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands., Cohen D; Department of Pathology, Leiden University Medical Center (LUMC), the Netherlands. Electronic address: d.cohen@lumc.nl.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Sep; Vol. 173, pp. 229-237. Date of Electronic Publication: 2022 Aug 04.
DOI: 10.1016/j.ejca.2022.06.030
Abstrakt: Introduction: Since the approval of neurotrophic tropomyosin receptor kinase (NTRK) tyrosine kinase inhibitors for fist-line advanced stage pan-cancer therapy, pathologists and molecular biologists have been facing a complex question: how should the large volume of specimens be screened for NTRK fusions? Immunohistochemistry is fast and cheap, but the sensitivity compared to RNA NGS is unclear.
Methods: We performed RNA-based next-generation sequencing on 1,329 cases and stained 24 NTRK-rearranged cases immunohistochemically with pan-TRK (ERP17341). Additionally, we performed a meta-analysis of the literature. After screening 580 studies, 200 additional NTRK-rearranged cases from 13 studies, analysed with sensitive molecular diagnostics as well as pan-TRK IHC, were included.
Results: In the included 224 NTRK-rearranged solid tumours, the sensitivity for pan-TRK IHC was 82% and the false-negative rate was 18%. NTRK3 fusions had more false negatives (27%) compared to NTRK1 (6%) and NTRK2 (14%) (p = 0.0006). Membranous, nuclear and peri-nuclear staining patterns strongly correlated with different fusion products, with membranous staining being more prevalent in NTRK1 and NTRK2, nuclear in NTRK3, and perinuclear in NTRK1.
Conclusion: Despite a reduction in the number of molecular analysis, using pan-TRK immunohistochemistry as a prescreening method to detect NTRK fusions in solid tumours will miss 18% of all NTRK-fused cases (especially involving NTRK3). Therefore, the most comprehensive and optimal option to detect NTRK fusions is to perform molecular testing on all eligible cases. However, in case of financial or logistical limitations, an immunohistochemistry-first approach is defensible in tumours with a low prevalence of NTRK fusions.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: